Oncologists should 'revisit' end-of-life care goals: Yale, MD Anderson study

Oncologists should 'revisit' end-of-life care goals: Yale, MD Anderson study
Becker's Hospital Review; by Ashleigh Hollowell; 5/22/24
Administering more treatments to advanced, end-of-life cancer patients did not increase their length of survival, according to a joint study from researchers at Yale Cancer Center in New Haven, Conn., and the University of Texas MD Anderson Cancer Center in Houston. Both the American Society of Clinical Oncology and the National Quality Forum have previously recommended a cancer quality metric aimed at reducing these therapies at the end of life, according to the study, which was published May 16 in JAMA Oncology.
Publisher's Note: See Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors for the JAMA Oncology article.